PanCare follow-up recommendations for surveillance of late effetcs
- Higher risk groups
- Alopecia
- Cerebrovascular problems
- Dental and oral problems
- Gastro-intestinal problems
- Peripheral neuropathy
- Health promotion
- Subsequent neoplasms
- Subsequent melanoma and non-melanoma skin cancer
- Cancer-related fatigue
- Psychosocial problems
- Mental health problems
- Chronic pain
- Neurocognitive problems
- Eye problems
- Craniofacial growth problems
- Spine scoliosis and kyphosis
- Lower urinary tract problems
- Obstetric problems
- Subsequent thyroid cancer
- Subsequent CNS neoplasms
- Subsequent breast cancer
- Subsequent colorectal cancer
- Impaired glucose metabolism and diabetes mellitus
- Dyslipidaemia
- Overweight and obesity
- Hypertension
- Bone problems
- Hypothalamic-pituitary (HP) axis problems
- Central precocious puberty (CPP)
- Ear problems
- Thyroid function problems
- Cardiac problems
- Coronary artery disease
- Pulmonary problems
- Renal problems
- Liver problems
- Spleen problems
- Male fertility problems and sexual dysfunction
- Premature ovarian insufficiency
SUBSEQUENT MELANOMA AND NON-MELANOMA SKIN CANCER
Consensus-based recommendation for surveillance of subsequent melanoma and non-melanoma skin cancer
This page is part of the PanCare follow-up recommendations for surveillance of late effects. Click here, for more information on these recommendations.
Click here, to read this recommendation in PLAIN language.
Who is at risk for melanoma and non-melanoma skin cancer?
CAYA cancer survivors treated with
- any radiotherapy, including TBI, predominantly in the radiotherapy field
- HSCT, especially with a history of skin GvHD
What problems might occur?
-
Basal cell carcinoma
- Squamous cell carcinoma
- Melanoma
What surveillance modality should be used and at what frequency should it be performed?
- Self-examination for new spots and changing moles, at least every 6 months
- History at least every 2 years, starting at entry into long-term follow-up
- Skin exam at least every 2 years, starting at entry into long-term follow-up
What should be done if abnormalities are identified?
- Refer to a dermatologist
Disclaimer
While PanCare strives to provide accurate and complete information that is up-to-date as of the date of publication, we acknowledge that the sequence of referral and diagnostic tests might vary according to the local and national healthcare system logistics.
It is recognised that survivors and their healthcare professionals have the final responsibility for making decisions concerning their long-term follow-up care. As such, they may choose to either adopt these recommendations or not to do so after individual informed discussion. It is good practice to document this decision.
In addition to regular surveillance, real-time awareness and prompt reporting of new symptoms and signs is essential to the early detection and timely treatment of late effects.
No warranty or representation, expressed or implied, is made concerning the accuracy, reliability, completeness, relevance, or timeliness of this information.
The PanCare materials are free to use for anyone aiming to inform about late effects and long-term survivorship care. However, no financial advantage may be achieved. All communication should reference PanCare and link to the PanCare website.